We use cookies for a better user experience. Read our Privacy Policy
I Agree
Rheumatology Therapeutics Market Trends, 2017-2025
Rheumatology illnesses mostly affect the body's supporting or linking structures, such as muscles, ligaments, joints, and tendons, as well as a few organs. In some forms of rheumatic illness, this condition is characterized by joint inflammation and affects the spine. There are about a hundred different forms of rheumatic illness. It is caused by a variety of hereditary and environmental causes, including a poor diet and a change in lifestyle, all of which can lead to rheumatic disorders. Rheumatology illnesses include ankylosing spondylitis, fibromyalgia, gout, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, reactive arthritis, and scleroderma. Rheumatology treatment includes exercises, drugs, and physical therapy, as well as surgery to repair joint injury. Increasing prevalence of rheumatology illnesses is estimated to bolster growth of the global rheumatology therapeutics market in the years to come. The management of rheumatologic symptoms can be aided by early intervention. For the treatment of rheumatologic illness, doctors use disease-modifying antirheumatic medicines (DMARDs). Rheumatology illnesses can be cured with appropriate nutrition, exercise, and medicine.
Increased spending in the healthcare business for funding research and development activities, together with technological improvements in the pharmaceutical area is expected boost sales in the global market. Fitness is becoming more popular throughout the world, which is likely to help the global rheumatology therapeutics market develop. The global market is growing due to rising healthcare spending among the middle-income population.
The treatment of rheumatic disorders, especially rheumatology therapies, is gaining in popularity amongst medical researchers and pharmaceutical companies throughout the world. The high prevalence of rheumatoid arthritis (RA), particularly amongst women, is likely to drive R&D in the rheumatic medicines industry. When the condition advances, RA causes persistent inflammation of the synovial membrane, which leads to joint damage. Overall, this has a negative influence on the quality of life of those who are impacted. In the treatment of RA, a variety of medication classes have arisen, the most notable of which are Disease Modifying Anti-Rheumatic Drugs (DMARDs). International organizations have been involved in establishing guidelines for pharmaceutical and non-pharmacological therapy, particularly for RA. The European League against Rheumatism is a good example (EULAR). Drug classifications are diverse and complicated.
Glucocorticoids (GC) are frequently used to control illness flare-ups and minimize disease severity. Improved synthetic DMARDs are the focus of new therapy recommendations. For instance, if a DMARD fails to work as a first-line treatment, physicians are looking towards biologic DMARDs. In the next few years, different tactics being attempted in the global rheumatology therapeutics market with the use of bDMARD are projected to enhance the landscape.
The emergence of biosimilars, on the other hand, is a key stumbling block for the global rheumatology therapeutics market. The rising demand for biosimilars may put a halt to the treatment of rheumatic disorders using traditional drugs. The rheumatic therapeutics industry is also being hampered by the patent expiration of various medications used to treat rheumatologist illnesses. For example, the Enbrels drug's patent expired in 2012.
Due to the substantial growth in the elderly population, which is plagued with various forms of rheumatic problems, North America is estimated to hold a significant share of the global rheumatology therapeutics market. In addition to that, the region's market has benefited from the use of biosimilars and biologics for the management of moderate to severe rheumatoid arthritis, as well as well-established healthcare facilities. In terms of market size, Europe lags behind North America. However, Asia Pacific is expected to dominate in terms of growth rate. This is due to the large number of people with rheumatoid arthritis and osteoarthritis, rising per capita healthcare spending, and the regulatory clearance of biosimilars for the treatment of a variety of rheumatic conditions.
Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., and other prominent firms operating in the global rheumatology therapeutics market is likely to account for majority share in the global rheumatology therapeutics market during the forecast period. Takeda Pharmaceutical, Amgen, Inc., Genentech, Inc., Novartis AG, Janssen Biotech, Inc., and Sanofi are among the other global participants in the industry.
Global Rheumatology Therapeutics Market is segmented as given below:
|
by Drug Class |
|
|
by Disease Indication |
|
|
by Route of Administration |
|
|
by Distribution Channel |
|
|
by Geography |
|
Rheumatology therapeutics market is expected to attain value of a US$ 52.96 bn by the end of 2025
Rheumatology therapeutics market is expected to expand with a CAGR of 2.7% over the forecast period from 2017 to 2025
Rheumatology therapeutics market is driven by increasing expenditure on healthcare from mid-earing population and rising prevalence of rheumatology diseases
North America accounts for a leading share in the global rheumatology therapeutics market owing to rapid rise in the elderly population
Key players operating in the global rheumatology therapeutics market include AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc.
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Rheumatology Therapeutics market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Key Industry Developments
4.1.2. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
4.1.3. Global Rheumatology Therapeutics Market Outlook
Chapter 5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Porter’s five forces analysis
Chapter 6. Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.3.3. Corticosteroids
6.3.4. Uric Acid Drugs
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
6.5. Key Trends
Chapter 7. Global Rheumatology Therapeutics Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
7.3.1. Rheumatoid Arthritis
7.3.2. Osteoarthritis
7.3.3. Gout
7.3.4. Psoriatic Arthritis
7.3.5. Ankylosing Spondylitis
7.3.6. Others
7.4. Market Attractiveness Analysis, by Disease Indication
7.5. Key Trends
Chapter 8. Global Rheumatology Therapeutics Market Analysis and Forecasts, by Route of Administration
8.1. Key Findings
8.2. Introduction
8.3. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
8.3.1. Parenteral
8.3.2. Oral
8.3.3. Topical
8.4. Market Attractiveness Analysis, by Route of Administration
8.5. Key Trends
Chapter 9. Global Rheumatology Therapeutics Market Analysis and Forecasts, by Distribution Channel
9.1. Key Findings
9.2. Introduction
9.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness Analysis, by Distribution Channel
9.5. Key Trends
Chapter 10. Global Rheumatology Therapeutics market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Global Market Scenario
10.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
10.3.1. North America
10.3.2. Europe
10.3.3. Asia Pacific
10.3.4. Latin America
10.3.5. Middle East & Africa
10.4. Market Attractiveness Analysis, by Region
Chapter 11. North America Rheumatology Therapeutics market Analysis and Forecast
11.1. Key Findings
11.2. Market size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
11.2.1. U.S.
11.2.2. Canada
11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
11.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
11.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
11.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.3.3. Corticosteroids
11.3.4. Uric Acid Drugs
11.3.5. Others
11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
11.4.1. Rheumatoid Arthritis
11.4.2. Osteoarthritis
11.4.3. Gout
11.4.4. Psoriatic Arthritis
11.4.5. Ankylosing Spondylitis
11.4.6. Others
11.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
11.5.1. Parenteral
11.5.2. Oral
11.5.3. Topical
11.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
11.6.1. Hospital Pharmacy
11.6.2. Retail Pharmacy
11.6.3. Online Pharmacy
11.7. Market Attractiveness Analysis
11.7.1. By Country/Sub-region
11.7.2. By Drug Class
11.7.3. By Disease Indication
11.7.4. By Route of Administration
11.7.5. By Distribution Channel
11.8. Key Trends
Chapter 12. Europe Rheumatology Therapeutics market Analysis and Forecast
12.1. Key Findings
12.2. Market size (US$ Mn) Forecast By Country, 2017-2025
12.2.1. Germany
12.2.2. U.K.
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7. Rest of Europe
12.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
12.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
12.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
12.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
12.3.3. Corticosteroids
12.3.4. Uric Acid Drugs
12.3.5. Others
12.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
12.4.1. Rheumatoid Arthritis
12.4.2. Osteoarthritis
12.4.3. Gout
12.4.4. Psoriatic Arthritis
12.4.5. Ankylosing Spondylitis
12.4.6. Others
12.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
12.5.1. Parenteral
12.5.2. Oral
12.5.3. Topical
12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Route of Administration
12.7.5. By Distribution Channel
12.8. Key Trends
Chapter 13. Asia Pacific Rheumatology Therapeutics market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
13.3.1. China
13.3.2. India
13.3.3. Japan
13.3.4. Australia & New Zealand
13.3.5. Rest of Asia Pacific
13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
13.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
13.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
13.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
13.4.3. Corticosteroids
13.4.4. Uric Acid Drugs
13.4.5. Others
13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
13.5.1. Rheumatoid Arthritis
13.5.2. Osteoarthritis
13.5.3. Gout
13.5.4. Psoriatic Arthritis
13.5.5. Ankylosing Spondylitis
13.5.6. Others
13.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
13.6.1. Parenteral
13.6.2. Oral
13.6.3. Topical
13.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.7.1. Hospital Pharmacy
13.7.2. Retail Pharmacy
13.7.3. Online Pharmacy
13.8. Market Attractiveness Analysis
13.8.1. By Country/Sub-region
13.8.2. By Drug Class
13.8.3. By Disease Indication
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.9. Key Trends
Chapter 14. Latin America Rheumatology Therapeutics market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
14.3.1. Brazil
14.3.2. Mexico
14.3.3. Rest of Latin America
14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
14.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
14.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
14.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
14.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
14.4.3. Corticosteroids
14.4.4. Uric Acid Drugs
14.4.5. Others
14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
14.5.1. Rheumatoid Arthritis
14.5.2. Osteoarthritis
14.5.3. Gout
14.5.4. Psoriatic Arthritis
14.5.5. Ankylosing Spondylitis
14.5.6. Others
14.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
14.6.1. Parenteral
14.6.2. Oral
14.6.3. Topical
14.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
14.7.1. Hospital Pharmacy
14.7.2. Retail Pharmacy
14.7.3. Online Pharmacy
14.8. Market Attractiveness Analysis
14.8.1. By Country/Sub-region
14.8.2. By Drug Class
14.8.3. By Disease Indication
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.9. Key Trends
Chapter 15. Middle East and Africa Rheumatology Therapeutics market Analysis and Forecast
15.1. Key Findings / Developments
15.2. Market Overview
15.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
15.3.1. GCC Countries
15.3.2. South Africa
15.3.3. Israel
15.3.4. Rest of Middle East and Africa
15.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
15.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
15.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
15.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
15.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
15.4.3. Corticosteroids
15.4.4. Uric Acid Drugs
15.4.5. Others
15.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
15.5.1. Rheumatoid Arthritis
15.5.2. Osteoarthritis
15.5.3. Gout
15.5.4. Psoriatic Arthritis
15.5.5. Ankylosing Spondylitis
15.5.6. Others
15.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
15.6.1. Parenteral
15.6.2. Oral
15.6.3. Topical
15.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
15.7.1. Hospital Pharmacy
15.7.2. Retail Pharmacy
15.7.3. Online Pharmacy
15.8. Market Attractiveness Analysis
15.8.1. By Country/Sub-region
15.8.2. By Drug Class
15.8.3. By Disease Indication
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.9. Key Trends
Chapter 16. Competition Landscape
16.1. Global rheumatology therapeutics Market Share, by Company, 2016
16.2. Market Player – Competition Matrix (By Tier and Size of companies)
16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.3.1. Amgen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. AbbVie, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Financial Overview
16.3.3.5. Strategic Overview
16.3.4. Janssen Biotech, Inc. (Johnson & Johnson)
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Financial Overview
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Financial Overview
16.3.5.5. Strategic Overview
16.3.6. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Financial Overview
16.3.6.5. Strategic Overview
16.3.7. Bristol-Myers Squibb Company
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Financial Overview
16.3.7.5. Strategic Overview
16.3.8. Merck & Co., Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Financial Overview
16.3.8.5. Strategic Overview
16.3.9. Sanofi
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Financial Overview
16.3.9.5. Strategic Overview
16.3.10. Takeda Pharmaceutical
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Financial Overview
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 06: Global rheumatology therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 11: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 12: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 16: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 17: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 18: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 22: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 23: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 24: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 26: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 28: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 29: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 30: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 31: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 32: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 33: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 34: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 35: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 36: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
List of Figures
Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Market Value Share, by Drug Class (2016)
Figure 03: Market Value Share, by Disease Indication (2016)
Figure 04: Market Value Share, by Route of Administration (2016)
Figure 05: Market Value Share, by Distribution Channel (2016)
Figure 06: Market Value Share, by Region (2016)
Figure 07: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Figure 09: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2015–2025
Figure 10: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
Figure 11: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Uric Acid Drugs, 2015–2025
Figure 12: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2015–2025
Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 15: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Rheumatoid Arthritis, 2015–2025
Figure 16: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Osteoarthritis, 2015–2025
Figure 17: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Gout, 2015–2025
Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Psoriatic Arthritis, 2015–2025
Figure 19: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ankylosing Spondylitis, 2015–2025
Figure 20: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2015–2025
Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 22: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 23: Global Rheumatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2015-2025
Figure 24: Global rheumatology therapeutics market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Parenteral, 2015–2025
Figure 25: Global Rheumatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Topical, 2015-2025
Figure 26: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 27: Global Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 28: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 29: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
Figure 30: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2025
Figure 31: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 32: Global rheumatology therapeutics Market Value Share Analysis, by Region, 2017 and 2025
Figure 33: Global rheumatology therapeutics Market Attractiveness Analysis, by Region, 2017-2025
Figure 34: North America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 35: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 36: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 37: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 38: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 39: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 40: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 41: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 42: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 43: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 44: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 45: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 46: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 47: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 48: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 49: Europe Rheumatology Therapeutics Market Attractiveness analysis, by Country/Sub-region, 2017–2025
Figure 50: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 51: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 52: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 53: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 54: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 55: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 56: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 57: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 58: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 59: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 60: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 61: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 62: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 63: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 64: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 65: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 66: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 67: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 68: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 69: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 70: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 71: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 72: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 73: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 74: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 75: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 76: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 77: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 78: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 79: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 80: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 81: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 82: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 83: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 84: Global rheumatology therapeutics Market Share, by Company, 2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes